Dual targeting of vascular endothelial growth factor (VEGF) with sorafenib and bevacizumab: Clinical and translational results von Azad, N. S., Annunziata, C., Barrett, T., Chen, C., Steinberg, S., Kwitkowski, V. E., McNally, D., Kotz, H., Minasian, L., Kohn, E. C.

Volltext

PCN122 DEVELOPMENT OF THE PATIENT-REPORTED VERSION OF THE COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS (PRO-CTCAE) von Basch, E, Reeve, B, Cleeland, C, Sloan, J, Schrag, D, Atkinson, TM, Mendoza, T, Hay, J, Abernethy, A, Minasian, L, Kwitkowski, V, Trentacosti, AM, Burke, L, Sit, L, Bruner, D

Volltext

Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab von Azad, N. S., Posadas, E. M., Kwitkowski, V. E., Annunziata, C. M., Barrett, T., Premkumar, A., Kotz, H. L., Sarosy, G. A., Minasian, L. M., Kohn, E. C.

Volltext

3 Overview of proteomics with emphasis on diagnosis and monitoring von Kohn, E.C., Posadas, E.M., Espina, V., Kwitkowski, V., Davidson, B., Petricoin, E.F., Liotta, L.

Volltext